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RBPs Play Important Roles in
Vascular Endothelial Dysfunction
Under Diabetic Conditions
Chunbo Yang, Sophia Kelaini, Rachel Caines and Andriana Margariti*
Centre for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
Diabetes is one of the major health care problems worldwide leading to huge suffering
and burden to patients and society. Diabetes is also considered as a cardiovascular
disorder because of the correlation between diabetes and an increased incidence of
cardiovascular disease. Vascular endothelial cell dysfunction is a major mediator of
diabetic vascular complications. It has been established that diabetes contributes to
significant alteration of the gene expression profile of vascular endothelial cells. Post-
transcriptional regulation by RNA binding proteins (RBPs) plays an important role in the
alteration of gene expression profile under diabetic conditions. The review focuses on the
roles and mechanisms of critical RBPs toward diabetic vascular endothelial dysfunction.
Deeper understanding of the post- transcriptional regulation by RBPs could lead to new
therapeutic strategies against diabetic manifestation in the future.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic, metabolic disorder characterized by hyperglycaemia due
to impaired glucose homeostasis, reduced insulin activity and insulin resistance (Rother, 2007).
Because of themultisystemmanifestations, DM is one of the primary health care problems affecting
435 million people in 2015 around the world (Ingelfinger and Jarcho, 2017). Diabetes related
complications are the 8th leading cause of death worldwide. Half of people who die from diabetic
complications are under the age of 60, while the rate of incidence is equal in both sexes (Shi and
Hu, 2014). There are two types of diabetes, namely, type 1 and 2. Type 1 diabetes (T1D) is caused by
an autoimmune attack on the β-cells of the pancreas, which lead to pancreatic islet inflammation
(insulitis), β-cell apoptosis and subsequent hyperglycemia due to low insulin production. T1D
patients need daily administration of insulin and are likely to suffer ketoacidosis, coma and death
(Størling and Pociot, 2017). T1D accounts for 10–15% of diabetes incidences, while Type 2 diabetes
(T2D) contributes to a majority of 85–90%. T2D is characterized by insulin resistance, defects in
insulin secretion, β-cell apoptosis and islet amyloid deposits. The glucose cannot be utilized by
target tissues such as liver and skeletal muscle, hence the blood glucose level increased (Rawshani
et al., 2017). The etiology of T2D is unknown, however, physiological, genetic, and environmental
factors such as obesity, family history and pollution are known to be risk factors (Stumvoll et al.,
2005). Diabetes triggers multisystemic complications such as cardiovascular diseases, neuropathy,
nephropathy etc. and the patients have higher predisposition of infection, cancer, and Alzheimer’s
disease (Harcourt et al., 2013; Schneider et al., 2016). Nowadays people see diabetes not only
as a metabolic disorder but also a cardiovascular disease because of the parallel occurrence of
cardiovascular complications along with diabetes. The intimate correlation between diabetes and
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the predisposition of cardiovascular disease has been well-
reported (Leon and Maddox, 2015). Diabetes is characterized by
a two- to four- fold increased risk of cardiovascular disease while
endothelial cell dysfunction is the initiating and perpetuating
factor in the development of vascular complications (Brownlee,
2001; Shi and Vanhoutte, 2017).
The endothelium is the monolayer of endothelial cells (ECs)
covering the lumen of blood vessels. In addition to providing
a physical barrier between tissues and the circulating blood,
vascular ECs play important roles in the maintenance of vascular
homeostasis under physiological conditions. The endothelium
is critical for the regulation of vasodilation, prevention of
platelet adhesion, aggregation and thrombogenesis, as well as
behavior of the underlying smoothmuscle cells. The endothelium
secretes various factors, regulating vessel integrity, blood
vessel development, metabolism, inflammation, cell adhesion,
angiogenesis, haemostasis, and vascular permeability (Sena et al.,
2013).
In diabetes, endothelial functions are compromised, including
increased permeability, disturbed vascular tone, aberrant
angiogenesis, enhanced adhesion, and deposition of monocytes
and platelets, leading to thrombogenesis. The most prevailing
mechanism of endothelial dysfunction is an increase in oxidative
stress and reactive oxygen species (ROS), which inactivates nitric
oxide (NO) and ablates its role in regulating vascular tone as
well as prevention of adhesion and aggregation of leukocytes
and platelets, smooth muscle cell proliferation, inflammation
and apoptosis (Vallance and Chan, 2001; Giacco and Brownlee,
2010). In addition, NO bioavailability is reduced due to down-
regulation of nitric oxide synthase (eNOS), the critical enzyme
in catalyzing the generation of NO from L-arginine (Sena et al.,
2008).
It has been established that hyperglycaemia contributes to
a significant alteration of gene expression profile in vascular
ECs. High throughput assays of the transcriptome have revealed
a plethora of candidate genes involved in extracellular matrix
(ECM) reorganization, angiogenesis, vascular tone, inflammatory
response, apoptosis, cell cycle, cell adhesion, coagulation, platelet
activation etc. (Table 1) (Stenina, 2005; Ambra et al., 2014;
Moradipoor et al., 2016).
The gene expression profile in vascular ECs is finely regulated
by both transcriptional and post- transcriptional regulation
systems. Post-transcriptional regulation includes processing of
the pre-mRNAs toward mature mRNAs as well as mRNA
transportation, quality control, mRNA decay and translational
regulation etc. (Whelan et al., 2012).
There are around 424 RNA-binding proteins (RBPs) encoded
by the human genome. Many of the RBPs are reportedly
dysregulated in diabetes (Keene, 2007; Vanderweyde et al.,
2013). For instance, HuR, hnRNP K, hnRNP F, IGF2BP2,
and LIN28 are dysregulated in diabetic nephropathy, QKI,
TTP and hnRNP C are related to atherosclerosis, CUGBP1,
RBFOX1 and eIF4E are associated with diabetic skeletal
muscle myopathy and LIN28, HuR and QKI are linked
to diabetic cardiomyopathy as well (Nutter and Kuyumcu-
Martinez, 2018) RBPs bind to a specific RNA sequence and/or
RNA structure to form ribonucleoprotein (RNP) complexes
TABLE 1 | Dysregulated genes and vascular dysfunctions under diabetic
conditions.
Vascular
functions
Dysregulated
genes under
diabetic conditions
Related vascular
dysfunctions
Angiogenesis and
cell junction
VEGF
KDR
FGF2
VE-Cadherin
Neovascularization and vascular
leakage
Vascular tone Cox-2
EDN-1
EDN-2
Enhancement of vascular
contractility
Inflammation IL3
IL8
MCP1
CX3CL1
Inflammatory infiltration
Apoptosis CASP1
CASP3
BAX
BCL2
Apoptosis of ECs
Intercellular
adhesion
ICAM-1
SELP
SELE
ITGB3
Adhesion of monocytes and
activated platelet
Cell matrix FN1
COL3A
LAMB1
MMP-1
MMP-9
Promoted matrix degradation
and accelerated atherogenesis
and reduced plaque stability
dynamically (Gerstberger et al., 2014; Heinrich et al., 2017).
RNA- binding domains (RBDs) encompassed in RBPs act as key
modules for RNA recognition (Lunde et al., 2007). The most
common RBDs exist in RBP of varying functions, including
the hnRNPK homology (KH) domain, RNA recognition
motif (RRM), double-stranded RNA-binding domain (dsRBD),
zinc finger (ZnF) motif, cold shock domain (CSD) etc.
(Gerstberger et al., 2014).
RBPs interact with target (pre)mRNAs at the 5′- and 3′-
untranslated regions (UTRs), as well as at non-coding (intronic)
and coding (exonic) regions and function in every aspect of
RNA processing to produce mature mRNA and regulate mRNA
localization, stability and translation (Gerstberger et al., 2014).
5′cap and 3′ poly(A) tail structures can be removed by decapping
enzymes and deadenylases to cause mRNA degradation (Roy and
Jacobson, 2013). Binding to cis-acting elements in the mRNA,
RBPs interact with decapping or deadenylation enzymes to
affect mRNA stability (Feigerlová and Battaglia-Hsu, 2017). For
instance, RBPs HuR and TTP bind to the AU-rich elements
(AREs) in the 3′UTRs of mRNA to promote stability or trigger
decay of mRNA (Brennan and Steitz, 2001) (Figure 1). Proper
function of these intricate post-transcriptional manipulations of
the RNA network is essential for the vascular endothelial system.
Many RBPs and RBP-regulated RNA network disruptions have
been implicated in the development of diabetic dysfunction of
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FIGURE 1 | RBPs regulate processing, Localization and stabilization of mRNAs.
the vascular endothelium (Scott et al., 2007). The current review
focuses on five critical RNA binding proteins HuR, TTP, SRSF1,
SRSF6, and QKI (Table 2).
HUR
HuR is a member of the Drosophila embryonic lethal abnormal
visual (ELAV) protein family that binds to mRNA PolyU- and
AU- rich elements and prevents RNase mediated degradation
(Chang and Hla, 2014; Pullmann and Rabb, 2014). HuR is
up-regulated and activated in diabetes by various mechanisms
including MiRNA regulators (MiR23 and MiR9) and protein
kinase C (PKC)-mediated phosphorylation (Amadio et al., 2010;
Jeyabal et al., 2016). Upon activation, HuR translocates from
nucleus to the cytoplasm to bind and affect the stability and
translation of target mRNAs (Govindaraju and Lee, 2013).
Vascular endothelial growth factor (VEGF) acts as a key
regulator in the process of neovascularization and angiogenesis.
In ECs from patients with diabetic retinopathy, HuR binds and
stabilizes VEGF which triggers endothelial proliferation,
migration and tube formation leading to pathological
angiogenesis (Amadio et al., 2010). When streptozotocin (STZ)-
induced diabetic rats were treated with intravitreal injection
of lipoplexes, a Nanosystem loaded with siRNA silencing HuR
expression, retinal HuR and VEGF are significantly decreased
and diabetic retinal damage is alleviated (Amadio et al., 2016).
Zhang et al. reported that when murine macrophages adhered to
the β2 integrin ligand intercellular adhesion molecule-1 (ICAM-
1), VEGF and matrix metalloproteinase-9 (MMP9) mRNAs
were stabilized. Whereas, in tissue-specific HuR knockout
mice, this mRNA stabilization effect was lost in bone marrow-
derived macrophages. Further functional study verified the
impaired recovery of blood flow and muscle neovascularization
post femoral artery ligation (Zhang et al., 2012). Therefore,
in contrary to its pathological angiogenic effects in diabetic
retinopathy, HuR contributes to promoting the repair of
damaged vascular endothelium via stabilization of VEGF.
Activation of vascular endothelial cells results in vascular
diseases such as sepsis and atherosclerosis. In human pulmonary
microvascular endothelial cells, HuR stabilized, and up-
regulated mRNA levels of tumor necrosis factor (TNF)-induced
interleukin-6 (IL-6) (Shi et al., 2012). Tiedje et al. reported
that HuR binding to ARE was mandatory to stabilize and
initiate translation of TNF at the endoplasmic reticulum
(ER) (Tiedje et al., 2012). Cheng et al. demonstrated that
HuR promoted endothelial activation by suppressing eNOS
expression (Cheng et al., 2013). HuR knockdown by MiR-146a in
vascular ECs negatively regulated inflammation via suppression
of pro-inflammatory NF-κB, MAPK signaling pathways and
downstream EGR transcription factors as well as decreases in
ICAM-1, VCAM-1, and adhesion of monocytes (Rhee et al.,
2010).
Sirtuin 1 (SIRT1) is the leading deacetylase in the SIRT
family that serves as a protector against environmental stresses
to promote cell survival (Chen et al., 2012). Vascular ECs
under hyperglycaemia showed decreased SIRT1 expression.
Abdelmohsen et al. reported that HuR bound to the 3
′
UTR of
SIRT1 mRNA, stabilizing and increasing SIRT1 expression levels.
Under oxidative stress, HuR was phosphorylated by ChK2 at
residue Ser-100 leading to segregation of the HuR-SIRT1 mRNA
complex. The degradation of separated SIRT1 mRNA coincided
with the decreased SIRT1 abundance and compromised cell
viability (Abdelmohsen et al., 2007).
TTP
Tristetraprolin (TTP), also known as zinc finger protein 36
homolog (ZFP36), belongs to the TIS11 family commonly
containing tandem CCCH zinc fingers. TTP binds to 3′ UTR
ARE region to induce destabilization and decay of mRNA by
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TABLE 2 | RNA binding proteins associated with endothelial dysfunctions under diabetic conditions.
Gene Description Mechanisms Target genes Clinical implications References
HuR ELAV (Embryonic
Lethal, Abnormal
Vision,
Drosophila)- Like 1
Binding to 3’ UTR to
stabilize mRNA VEGF
MMP9
TN Fα
IL6
SIRT1
Knockdown of HuR alleviated
diabetic retinal damages and
suppressed monocyte adhesion
Abdelmohsen
et al., 2007; Rhee
et al., 2010; Zhang
et al., 2012;
Amadio et al.,
2016
TTP Tristetraprolin Binding to 3’ UTR to Induce
mRNA decay by recruitment
of deadenylation and
decapping complexes
VEGF
TNFα
IL6
P65
HDAC1,3,7
CD36
HIF1α
TTP inhibited inflammation through
TNFa/NFKB and suppressed
atherosclerosis through regulation of
CD36
Carballo and
Blackshear, 2001;
Ciais et al., 2004;
Liang et al., 2009;
Dai et al., 2014
SRSF1 Serine And
Arginine Rich
Splicing Factor 1
Alternative splicing of VEGF
pre-mRNA adopting PSS in
exon 8 to favor
pro-angiogenic VEGF165
VEGF Inhibition of SRSF1 activity switched
VEGF splicing from pro- to
anti-anglogenic and reduced
neovascularization
Nowak et al.,
2008;
Peiris-Pagès,
2012; Mavrou
et al., 2015;
Batson et al., 2017
SRSF6 Serine And
Arginine Rich
Splicing Factor 6
Alternative splicing of VEGF
pre mRNA adopting DSS in
exon 8 to favor
anti-angiogenic VEGF165b
VEGF intravitreal application of recombinant
VEGF165b reduced the
neovascularization of the retina and
the normally vascularized area was
increased
Nowak et al.,
2008;
Peiris-Pagès,
2012
QKI Quaking Homolog,
KH Domain RNA
Binding
Binding to 3
′
UTR of STAT3
to stabilize mRNA or
regulated translation.
STAT3
VE-cadherin
VEGFR2
Fox01
β-catenin
Neovascularization and blood flow
recovery were improved by
transplantation of QKI5 over
expressing IPS-ECs in the hind limb
ischemia model; in vivo reduction of
QKI increased vascular leakage;
GKI-haploinsufficient patient showed
suppressed foam cell formation
implicating the suppression of
atherosclerosis.
Puthanveetil et al.,
2012; de Bruin
et al., 2016a,b;
Cochrane et al.,
2017
recruiting deadenylation and decapping complexes (Lai et al.,
2000; Lykke-Andersen and Wagner, 2005). mRNA- decapping
enzymes DCP1A and DCP2, CCR4-NOT deadenylase, the 5′-3′
exoribonuclease 1 (XRN1), exosome complex endonuclease PM-
SCl75 and argonaute 2 (AGO2) are important components of the
mRNA decay machinery that directly binds to TTP (Fabian et al.,
2013).
Both TTP and HuR bind to ARE elements, whereas studies
have shown that ARE-containing mRNAs are stabilized by HuR
but destabilized by TTP. There are three members in the TTP
family, TTP, TTPL1 and TTPL2 who share the activity to
destabilize mRNA. TTPL1 interacts with the two ARE elements
in the 3′ UTR of VEGF mRNA to trigger degradation (Ciais
et al., 2004), which was opposite to the effect of HuR. In another
case, HuR stabilized and up-regulated IL-6 mRNA in human
pulmonary vascular ECs, whereas TTP promoted IL- 6 mRNA
degradation (Sauer et al., 2006).
Apart from IL-6, a plethora of mRNAs of inflammatory
modulators have been reported to be destabilized by TTP,
such as interleukin, interferon and chemokine ligand family
members (Xin et al., 2014). TTP was discovered to be readily
stimulated by insulin (Lai et al., 1990) and was well-characterized
in immune functions (Sanduja et al., 2011). TTP-deficient
mice showed severe, complex inflammatory phenotype such
as cachexia, arthritis and autoimmunity. Such phenotypes
were ameliorated by treatment with anti-TNFα antibody or
backcrossing with TNFR1 knockout mice, suggesting that
TTP suppressed inflammation through inhibition of TNFα
production (Taylor et al., 1996; Carballo and Blackshear,
2001).
NF-κB mediates the major inflammatory signal pathways
and aberrant NF-κB activation is related to tissue damage and
inflammatory disorders such as atherosclerosis and arthritis
(Pfitzner et al., 2004; O’Neill, 2006). TTP physically interacts
with the p65 subunit of NF-κB and functions as a corepressor of
p65/NF-κB. Overexpression of TTP inhibited NF-κB- dependent
transcription. TTP is also associated with histone deacetylases
HDAC1, −3, and −7 in vivo. HDAC1 or HDAC3 knockdown
by histone deacetylase inhibitors or small interfering RNA
completely or partly ablated the repression of TTP on NF-
κB reporter activation (Liang et al., 2009). TTP repressed the
expression of inflammatory cytokines in target cells via inhibition
of NF-κB transcriptional activation and destabilization of the
bound cytokine mRNAs (Figure 1).
Frontiers in Physiology | www.frontiersin.org 4 September 2018 | Volume 9 | Article 1310
Yang et al. RBPs and Diabetic Vascular Endothelial Dysfunction
Vascular endothelial dysfunction was also observed in TTP-
deficient mice (Bollmann et al., 2014). TTP−/− mice showed
stabilized and up-regulated NADPH oxidase 2 mRNA, which
was associated with enhanced levels of ROS and nitrogen
species (RNS). The alteration of ROS and RNS level was highly
related to the disruption of acetylcholine-induced NO-mediated
vasorelaxation.
Zhang et al. investigated the regulation of TTP on
inflammation in vascular ECs and its direct binding to target
cytokine mRNAs (Zhang et al., 2013). Healthy aorta showed
minimal expression of TTP which was significantly increased
in ECs overlying atherosclerotic lesions. TTP upregulation
was also observed in macrophage foam cells of atherosclerosis.
After migration into the subendothelial arterial space, the
monocytes readily differentiate into macrophages and take in
modified low-density lipoprotein (LDL) to form foam cells
which are essential for atherosclerosis. The uptake of oxidized
low-density lipoprotein (oxLDL) by macrophages is mediated
by the scavenger receptor CD36. Dai et al (Dai et al., 2014)
revealed that TTP, which bound to ARE in the 3′ UTR, promoted
CD36 mRNA degradation. Therefore, TTP may act as an
important inhibitor of macrophage foam-cell formation to deter
atherosclerosis.
Hypoxia-inducible factor 1 (HIF-1) is an important regulator
of vascular ECs to direct their response to changes of
environmental oxygenation. A variety of genes related to glucose
metabolism and angiogenesis are regulated by HIF-1(Dewhirst
et al., 2008). Chamboredon et al. analyzed the regulation of
HIF-1α mRNA expression in ECs under hypoxic conditions
and revealed that hypoxia-induced down-regulation of HIF-1α
mRNA in ECs was mediated by TTP, which bound specifically
to HIF-1α 3
′
UTR. The decrease in the half-life of luciferase
HIF-1α-3’UTR reporter transcript with prolonged hypoxia was
mediated by TTP. While knockdown of TTP in ECs reversed the
decrease of HIF-1α mRNA induced by hypoxia (Chamboredon
et al., 2011).
SRSF1/6
Splicing is one of the key steps of RNA processing toward
mature mRNA including intron removal from the pre-mRNA
and subsequent exon ligation. By alternative splicing, selection
of various subsets of exons results in different isoforms of
transcripts generated from the same gene. Alternative splicing is
a major origination of proteins with different functions, but in
some cases abnormal RNA splicing can lead to disorders (Feero
et al., 2010).
The VEGF gene plays a big part in the processes of
vascularization and angiogenesis. The VEGF mRNAs are derived
from eight exons to encode at least six protein isoforms. These
products are termed VEGF121, VEGF165, VEGF189, etc. based
on the number of amino acids, among which VEGF165 is the
main isoform. When the distal splice site (DSS) in exon 8 is
selected, the last exon turns to exon 8b resulting in a novel
family of isoforms of VEGF, termed VEGF121b, VEGF165b,
VEGF189b, etc. The first identified member of this family
was VEGF165b, which is the only one whose effect on EC
functions has been investigated (Bates et al., 2002). The produced
proteins of the two families have different C-terminal amino
acid sequences. During alternative splicing, when the proximal
splice site (PSS) is selected, the C-terminal codes for CDKPRR
to form VEGF165, while the selection of distal splice site (DSS)
results in the C-terminal coding of SLTRKD to form VEGF165b
isoform. In spite of the encompassment of receptor-binding
domains, the VEGF165b isoform is not able to activate VEGF-
R2. What’s more, it acts as a competitor to inhibit the normal
functions of VEGF165 on the regulation of EC proliferation,
migration and vasodilation (Ladomery et al., 2007). Therefore,
the alternative splicing products of VEGF165 and VEGF165b
function as pro- or anti-angiogenic regulators separately (Peiris-
Pagès, 2012). In the normal vitreous VEGF165b isoforms account
for nearly two thirds of the total VEGF. In the diabetic vitreous,
however, VEGF165 is significantly increased and becomes the
dominant form Perrin et al. (2005). In the circumstance of
diabetic retinopathy, the splicing of VEGF switches to the pro-
angiogenic isoform (VEGF165) to favor vascularization in the
retina.
The serine/arginine-rich (SR) proteins play critical roles in the
alternative splicing of the VEGF RNA transcript. Computational
sequence analysis of the VEGF gene revealed a predicted binding
site for Serine/Arginine Rich Splicing Factor 1 (SRSF1) before the
DSS, and a predicted SRSF6 binding site behind the DSS (Peiris-
Pagès, 2012). When SRSF1 binds to the pre-mRNA of VEGF,
the PSS in exon 8 is preferred to generate VEGF165 isoform.
When SRSF6 binds to the pre-mRNA, the DSS dominates to form
VEGF165b (Nowak et al., 2008). SRSF1 ismodulated by upstream
regulators SR protein kinases 1 and 2 (SRPK1/2). SPRK1 can
be inhibited by small molecule inhibitors or down-regulated
by RNA interference (RNAi) to block activation and nuclear
transportation of SRSF1. SRSF1 inhibition consequently switches
the selection of PSS to DSS and benefits the generation of anti-
angiogenic VEGF165b isoform (Amin et al., 2011; Mavrou et al.,
2015).
Through PKC-induced activation of SRPK1, IGF1 and TNFα
support the selection of PSS in exon 8, whilst TGFβ activates
p38 mitogen-activated kinases (p38 MAPK) through Clk1
and phosphorylates SRSF6, which favor the usage of DSS
element (Harper and Bates, 2008; Nowak et al., 2008). Small
molecule inhibitors of SRPK1, such as SRPIN340, MVRL09,
and SPHINX31 are potent regulators to inhibit the binding
of PSS in exon 8 by SRSF1 to elevate the level of VEGF165b
through alternative splicing. In an animal model of retinal
angiogenesis, application of SRPK1 inhibitor greatly inhibited
activation of SRSF1, switching VEGF splicing from the pro-
to anti-angiogenic form to block neovascularization (Gammons
et al., 2013a,b; Batson et al., 2017). Injection of SRPK1/2 inhibitor
SRPIN340 into the retina of an oxygen-induced retinopathy
mouse model significantly reduced the neovascular area of
the retina and the normally vascularized area was increased,
which was equivalent to the effect of intravitreal application of
recombinant VEGF165b. Based on these findings, modulation
of VEGF165/VEGF165b balance by regulation of alternative
splicing machinery may be a novel therapeutic strategy for
diabetic retinopathy and other vascular disorders (Nowak et al.,
2010).
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QKI
Quaking (QKI) is an RNA binding protein belonging to the
Signal Transduction and Activation of RNA (STAR) protein
family which contain SH2 and SH3 domains, an RNA-binding
motif (e.g. a KH domain) and phosphorylation sites. This
implies they may play a role in the splicing of pre-mRNAs
(Vernet and Artzt, 1997), mRNA nuclear exportation, mRNA
stability and translation into the subsequent protein. They may
also be involved in some signal transduction pathways (Justice
and Hirschi, 2010). There are several QKI isoforms, three of
which (QKI5, QKI6 and QKI7) have been linked to vascular
development. Each of these isoforms holds different carboxy-
terminal ends but matching RNA binding domains (Chénard
and Richard, 2008). QKI is generally required in endothelial
barrier function maintenance as it increases VE-cadherin and
β-catenin expression in epithelial intercellular junctions. These
three QKI isoforms are present in ECs, with QKI5 being the
most abundant (de Bruin et al., 2016b). QKI gene has been
discovered in functional studies to be critical in the formation
and remodeling of embryonic blood vessels (Noveroske et al.,
2002). The expression of QKI was observed in the yolk sac
endoderm and homozygous QKk2 allele was found to be lethal
to the embryos due to disrupted vasculature development.
Forkhead box O1 (FoxO1) belongs to the forkhead family
of transcription factors that participates in a variety of
important biological events including cell proliferation, cell
death, immunologic reaction, regulation of metabolism in
response to oxidative stress etc. (Puthanveetil et al., 2013). Studies
have revealed the involvement of FoxO1 in the development
of cardiovascular diseases and diabetes (Puthanveetil et al.,
2012). In diabetes, the activated FoxO1 was associated with the
dysregulation of metabolic homeostasis and activation of cell
death signaling. Studies have revealed the decreased expression
of QKI5 in the myocardium of ob/ob diabetic mice. When QKI5
expression was up-regulated, FoxO1 expression was repressed
and the NS and ER stresses as well as ischemia/reperfusion injury
alleviated. By RNA co-immunoprecipitation the interaction
between QKI5 and FoxO1 mRNA was verified. When QKI5
was overexpressed the half-life of FoxO1 mRNA was shortened,
suggesting the negative effect of QKI5 on FoxO1 mRNA stability.
Previous work from our lab demonstrated that QKI5 was
suppressed in heart vessels isolated from diabetic mice compared
to healthy controls, suggesting a role of QKI5 in vascular
dysfunction under diabetic conditions. Using the model of
induced pluripotent stem (iPS) cell differentiation toward ECs,
our recent paper (Cochrane et al., 2017) reported a critical role
of QKI5 in the generation of ECs from iPS cells via stabilization
of CD144 and activation of VEGFR2 through STAT3 signaling.
RNA immunoprecipitation confirmed the direct binding of
QKI5 to the 3’ UTR of STAT3 to promote mRNA stability.
Remarkably, angiogenesis, neovascularization, and blood flow
recovery were significantly improved by transplantation of QKI5
overexpressing iPS-ECs in the animal model of experimental
hind limb ischemia. These findings suggest that QKI5 down-
regulation in diabetes may contribute to vascular complications
resulting from EC dysfunction and probably become a novel
target for therapeutic treatment of diabetes. Meanwhile, QKI5
induced the splicing factor SF3B1 during EC differentiation in a
time dependent manner, implying that QKI-5 contributed to EC
induction from iPSCs as an important splicing regulator.
QKI was also reported to participate in the regulation of
macrophage differentiation from monocytes (de Bruin et al.,
2016a). QKI showed low levels of expression in monocytes
and early human atherosclerotic lesions. When naïve human
monocytes were converted to macrophages with GM-CSF or M-
CSF, the expression of QKI protein isoforms was significantly
increased. Consistently, the examination of CD68+ macrophages
in advanced atherosclerotic lesions revealed high abundance of
QKI. In the QKI-haploinsufficient patient, foam cell formation
was suppressed due to limited differentiation of macrophages
from monocytes and subsequent reduced uptake of oxLDL
along with decreased QKI expression. These studies illustrated
the key role for QKI as a post-transcriptional regulator in
the determination of macrophage fate and development of
atherosclerosis (de Bruin et al., 2016b).
Given the observation that QKI isoforms were highly
expressed in the healthy vascular endothelium in comparison
with smooth muscle (van der Veer et al., 2013), de Bruin
et al. studied the relevance for QKI and endothelial functions
and underlying mechanisms. Both VE-cadherin and β-catenin
were predicted to harbor high-affinity Quaking Response
Element (QRE) (NACUAAY-N1–20-UAAY) in the 3′ UTRs of
their mRNAs (Galarneau and Richard, 2005), suggesting their
possible target identity of QKI which was confirmed by RNA
immunoprecipitation of both mRNAs by QKI antibody. With
QKI overexpression, luciferase- reporter assay with the 3′ UTRs
of both genes achieved significant enhancement of luciferase
activity, which was diminished when QKI was repressed. When
QKI was knockdown by shRNA in the ECs, neither VE-cadherin
nor β-catenin mRNA was significantly reduced, but their protein
levels were decreased. For functional study, ECs with QKI
knockdown failed to form a proper monolayer of high resistance,
although their adherence and spread capacities were not affected.
In vivo reduction of QKI resulted in a significant 40% increase
of vascular leakage. Therefore, the translation of VE-cadherin
and β-catenin was regulated by QKI through direct binding to
3′ UTRs. Reduced QKI expression resulted in the decrease of
VE-cadherin and β-catenin proteins and subsequent impaired
endothelial barrier function leading to vascular leakage.
LncRNAs AND RBPS IN ENDOTHELIAL
CELLS UNDER DIABETIC CONDITIONS
Most of current research is centered on protein-coding RNAs,
however, noncoding RNAs (ncRNAs) including long noncoding
RNAs (LncRNAs) account for themajority of genome transcripts.
Cooperating with RNA-binding proteins, LncRNAs participate in
all aspects of biological processes and their importance is widely
recognized. LncRNAs are >200 nucleotide long RNA transcripts
which lack protein-coding potential (Yang et al., 2014). LncRNAs
regulate gene expression at all levels through modulation of
epigenetic machineries, recruitment of RNA-binding proteins,
function as decoys and interact with miRNAs etc. Growing
evidence has revealed the correlation of disrupted lncRNA
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levels and a variety of human diseases, including diabetes. A
number of LncRNAs have been reported to be dysregulated under
diabetic conditions, such as MALAT1, MEG3, MIAT, RNCR3,
and ANRIL.
Metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) was significantly increased in retinal endothelial cells
of STZ-induced diabetic rats and db/db mice or high glucose
treated human umbilical vein endothelial cells (HUVEC) (Liu
et al., 2014; Yan et al., 2014; Puthanveetil et al., 2015) indicating
its involvement in the development of diabetic retinopathy
and endothelial dysfunction. Knockdown of MALAT1 by
intraocular injection of shRNA ameliorated retinal vascular
dysfunctions of cell barrier defects, pericyte loss, capillary
degeneration, and retinal inflammation. In vitro assays revealed
the decreased retinal endothelial cell proliferation, migration
and tube formation with MALAT1 downregulation. It is also
reported that MALAT1 knockdown decreased the level of ROS in
endothelial cells under hyperglycaemic conditions (Puthanveetil
et al., 2015).
MALAT1 binds to the splicing factor SRSF1 directly and
influences its phosphorylation, distribution in nuclear speckle
domains and alternative splicing function (Tripathi et al.,
2010). Depletion of MALAT1 or SRSF1 led to the increase
of anti-angiogenic VEGF isoform VEGF165b. Tube formation
assay of endothelial cells in the presence of conditioned
medium from modified SKBR3 cells showed that in SRSF1 and
MALAT1 interfered scenarios the angiogenic capacity of ECs
was significantly decreased (Pruszko et al., 2017). Liu et al.
reported that MALAT1 regulated the function of endothelial
cells through the p38/MAPK signaling pathway (Liu et al.,
2014). The cell proliferation induced by MALAT1 was blocked
by p38/MAPK pathway inhibitor SB203580 or p38 siRNA
and p38 stimulated phosphorylation was blunted by MALAT1
knockdown. The crosstalk between MALAT1 and p38/MAPK
pathway may become a novel strategy for the therapy of diabetes-
related microvascular complications. With MALAT1 silenced,
the S-phage endothelial cyclins CCNA2, CCNB1, and CCNB2
were significantly downregulated, while cell cycle inhibitory
genes p21 and p27Kip1 increased (Michalik et al., 2014). More
study is still required to elucidate the mechanisms of MALAT1
effects on cell signaling and cell cycle regulation.
Myocardial infarction associated transcript (MIAT) is another
LncRNA identified to be upregulated under diabetic conditions
in retinal endothelial cells and fibrovascular membrane of
diabetic patients (Strawbridge et al., 2011; Yan et al., 2015).
In vitro, MIAT knockdown inhibited EC proliferation under
hyperglycaemic conditiona and in vivo downregulation of MIAT
in STZ diabetic rats alleviated the retinal vascular dysfunctions
of pericyte loss, vascular degeneration and inflammation. MIAT
possesses a tandem UACUAAC repeat motif and binds directly
to the splicing factors SRSF1, QKI, Cef3 to form nuclear bodies
(Tsuiji et al., 2011; Barry et al., 2014). The UACUAAC repeat
motif binds to SRSF1 with a higher affinity than the divergent
branch point sequence in mammals and therefore may modulate
the alternative splicing of VEGF in favor of angiogenesis. MIAT
also competes with miR-150 and miR-29b in retinal endothelial
cells to regulate VEGFA level and apoptosis (Yan et al., 2015;
Zhang J. et al., 2017).
Antisense Noncoding RNA in the INK4 Locus (ANRIL) is a
3.8 kb antisense RNA to INK4 locus. ANRIL has been found to
be associated with vascular dysfunction in diabetes (Congrains
et al., 2013). ANRIL level elevationwas observed in human retinal
endothelial cells exposed to high glucose and also the retina of
diabetic animals, while overexpression of ANRIL upregulated
VEGF expression (Thomas et al., 2017; Zhang B. et al., 2017).
The increased retinal microvascular permeability in diabetic mice
was alleviated by ANRIL knockout, which was in consistence
with the dynamics of VEGF level. In human retinal endothelial
cells exposed to high glucose, the key components of PRC
complex EZH2 and p300 were significantly increased, while with
ANRIL knockdown the dysregulation was corrected. VEGF was
found to be regulated by miR200b through PRC complex and
p300 and RNA-IP assay verified the direct binding of ANRIL
to EZH2 and p300, indicating that upregulated ANRIL induced
VEGF generation in high glucose treated ECs through interaction
with PRC complex and p300. Moreover, by recruitment of PRC
complexes, ANRIL epigenetically suppressed the expression of
cell cycle regulators p15 and p16 which contain an overlapping
sequence with ANRIL in the promoter region (Yap et al., 2010;
Kotake et al., 2011).
It was reported that ectopic expression of ANRIL promoted
angiogenesis by stimulation of NFκB signaling (Zhang B.
et al., 2017). Moreover, in vascular ECs, TNFα induced
ANRIL expression through NFκB and ANRIL interacted with
PRC-associated transcriptional factor YY1 to regulate gene
expression of IL6 and IL8 (Holdt et al., 2013; Zhou et al.,
2016). Thus, the ANRIL- NFκB feedback loop may serve as
a target to protect endothelial cells against dysfunction and
atherosclerosis.
Retinal non-coding RNA3 (RNCR3) was first identified
during mouse retinal development with dynamic expression
(Blackshaw et al., 2004). RNCR3 was significantly up- regulated
in retinas of diabetic animals and endothelial cells upon high
glucose exposure. In vivo knockdown of RNCR3 ameliorated the
diabetes-induced vascular dysfunctions of acellular capillaries,
vascular leakage and inflammation. In vitro knockdown of
RNCR3 suppressed EC proliferation, viability, migration and
tube formation (Shan et al., 2016, 2017). It was revealed that
RNCR3 functioned as a competing endogenous RNA (ceRNA)
to regulate KLF2 levels by sponging miR-185-5p in endothelial
cells.
Opposite to the above LncRNAs, maternally expressed gene
3 (MEG3) was reported to be decreased in retinal ECs of STZ
diabetic mice (Qiu et al., 2016). In vivo knockdown of MEG3
led to retinal vascular dysfunctions of capillary degeneration,
microvascular leakage and inflammation. In vitro knockdown
of MEG3 in retinal vascular endothelial cells compromised
EC angiogenic potential which was mediated by activation of
PI3k/Akt signaling pathway.
Zhou et al. found that MEG3 interacted with p53 and
overexpression of MEG3 enhanced p53 level and stimulated p53-
dependent transcription implicating the involvement of p53 in
the functioning of MEG3 (Zhou et al., 2007). As it is known
that p53 binds to the VEGFA promoter and negatively regulates
its transcription (Qin et al., 2006). Therefore, downregulation
of MEG3 may contribute to the neovascularization and leakage
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of diabetic retinopathy through p53 suppression and subsequent
induction of VEGF.
RBP-BASED THERAPIES AND FUTURE
PERSPECTIVE
As RBP-regulated RNA networks play a critical role in the
development of diabetic vascular manifestations, targeting
the candidate RBPs or RBP-RNA interactions could be
a promising therapeutic strategy against diabetic vascular
endothelial dysfunction.
Some RBPs per se are promising treatments for diabetic
disorders. For instance, tristetraprolin (TTP) acts against
diabetic inflammation and atherosclerosis through degradation
of pro-inflammatory cytokines. TTP knockout mice showed
overexpression of the potent pro-inflammatory cytokine TNFα
and severe inflammatory phenotypes (Carballo et al., 1998).
Inversely, TTP overexpression exerted profound suppression
effect on inflammatory disease models (Patial et al., 2016).
Kirkwood et al. reported the study on a rat model of
periodontitis induced by intra-oral injection of LPS. When
TTP overexpression was achieved by local application of an
adenovirus expression vector, the complications of bone loss and
inflammatory infiltration were significantly alleviated and the
level of local cytokines was markedly reduced (Patil et al., 2008).
Diabetic vascular complications feature inflammatory events
and TNFα is implicated as an important mediator cytokine of
inflammation in diabetes. Therefore, the discoveries from animal
studies implies the possible beneficial effects of TTP application
on diabetic inflammation conditions.
Under various pathologic conditions such as age-related
macular degeneration (AMD) and diabetic retinopathy (DR),
VEGF serves as a key mitogen to stimulate angiogenesis.
Anti-VEGF antibodies have emerged as clinical treatment
against AMD and DR. However, intravitreal injection of VEGF
antibodies may harbor the risks of various complications,
such as infection, inflammation and vitreous hemorrhage
(Ventrice et al., 2013). Therefore, interest has grown to
invent more effective drugs (e.g., small molecules) and safer
methods (e.g., eye drop, ointment) of drug delivery to deal
with neovascularization complications. Inhibition of serine-
arginine protein kinase 1 (SRPK1) promotes the switch from
the pro-angiogenic isoform VEGF165 to the anti-angiogenic
isoform VEGF165b and suppresses pathologic angiogenesis
(Dong et al., 2013). Using a computational protocol combined
with a pharmacophore-based database search, Morooka et al.
identified a new small molecule, SRPIN803, that inhibits both
casein kinase 2 (CK2) and SRPK1 to suppress VEGF generation
synergistically. In a laser-induced choroidal neovascularization
mouse model, topical administration of SRPIN803 substantially
suppressed intraocular neovascularization, suggesting SRPIN803
as a promising therapeutic drug for pathologic angiogenesis.
(Morooka et al., 2015).
In diabetic conditions, highly expressed HuR translocates
from nucleus to cytoplasm to bind and stabilize VEGF which
triggers pathological angiogenesis. Amadio et al. carried out
intravitreal injection of nanosystems loaded with siRNA against
HuR (lipoplexes) to treat streptozotocin (STZ)-induced diabetic
retinopathy in rats. The results showed that retinal HuR and
VEGF were significantly silenced by HuR siRNA treatment
and diabetic retinal damage was rescued (Amadio et al.,
2016).
Anti-sense oligos (ASOs) are short single-stranded
deoxyribonucleotides complementary to sense strand nucleic
acid sequences. ASOs bind to target RNA sites and regulate
the expression of genes by several mechanisms, including
modulation of RNA stability, modification of RBP binding
to RNA, regulation of RNA splicing, and mRNA translation
(Lundin et al., 2015; Bishop, 2017). Some ASOs have progressed
to human clinical trials for disease treatment, including cancer,
diabetes, neurodegenerative disorders, and muscular dystrophy.
Alternative polyadenylation of the KDR gene gives rise to two
protein products with different functions, membrane-bound
KDR (mbKDR) and soluble KDR (sKDR). sKDR functions
as antagonist of lymphangiogenesis due to the lack of a
tyrosine kinase domain. Accordingly, an antisense morpholino
oligomer was designed complementary to the exon 13-intron
13 junction sequence to increase sKDR at the expense of
mbKDR, thereby suppressing both haemangiogenesis and
lymphangiogenesis. Uehara et al. demonstrated the suppression
of laser choroidal neovascularization by intravitreal morpholino
injection. Furthermore, subconjunctival application of the
morpholino significantly inhibited corneal angiogenesis,
lymphangiogenesis as well as graft rejection after transplantation
in the mouse cornea. (Uehara et al., 2013). In conclusion,
the post-transcriptional dysregulation of gene expression
by RBPs plays important roles in the development and
progression of diabetic endothelial dysfunction. The emergence
and advancement of high throughput technologies enables
the identification of RNA targets of RBPs, which offers
novel insight into the mechanisms of diabetic disorders.
Our deepened understanding of the mechanisms of RNA
transcripts, as well as the critical regulatory roles played
by RBPs enables the potential to provide novel therapeutic
options for diabetic patients. In terms of the designation
and application of RBP-RNA based therapeutic strategies,
caution is necessary to ensure the requirement of safety and
accuracy is fulfilled. The advances on specificity and efficacy
of RBP-RNA treatments are currently being investigated.
The future will see the possible inclusion of these smart
therapeutic modalities in the therapeutic field to combat diabetic
complications.
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